Pane budiriro ichangoburwa mugomarara remapapu risiri diki. A mhando kuchengetedza iyo inogona kurapa isiri-diki kenza yemapapu kenza (NSCLC) yakasangana nhanho ye3 kiriniki kubvumidzwa uye ine yakakura therapeudic kukanganisa kune isiri-diki maseru mapapu chirwere. Izvozvi zvave kuwanikwa mune mashoma nyika.
As an anti-idiotype monoclonal antibody, the vaccine enables lung cancer patients to respond strongly to specific glycosylated gangliosides (NeuGcGM3) in cancer cells. Compared with the best supportive care, lung jekiseni regomarara inogona kuvandudza mwero wekupona kwevarwere vane nhanho yekudzokera uye yepamusoro (nhanho IIIB / IV) NSCLC.
Rather than numerous warm blooded creatures, including gorillas, we can’t recognize the nearness of NeuGcGM3 gangliosides in typical human tissues and liquids. Be that as it may, NeuGcGM3 gangliosides are profoundly communicated in certain human malignant growth cells. In non-little cell lung malignancy tests, gangliosides were identified in over 90% of non-little cell lung tumors. Thusly, NeuGcGM3 ganglioside can be utilized as a ground-breaking objective for lung malignant growth antibodies.
Mushure mekusafungidzirwa fomati inogadzira yakajeka masoja ekudzivirira an antigen, inogona kugadzira masoja ekudzivirira kurwisa iyo yakasarudzika yeiyo huru antigen, iyo inogona kudzora kusagadzikana fomati kubva mukati. Mukumuka kwekubaiwa jekiseni kupokana neiyi mapapu yakaipa kukura kuchengetedza, it can advance the generation of antibodies against this antigen, assigned Ab1. These Ab1 antibodies are fit for delivering a progression of hostile to idiotypic antibodies, assigned Ab2. The idiotypes of these exceptional antibodies are fused into the antigen-restricting site of Ab1, with the goal that these extraordinary antibodies produce a particular resistant reaction to regular antigens. Hence, vaccination with Ab2 immunizer can advance the creation of Ab3 (hostile to against idiotype neutralizer), and this Ab3 counter acting agent can perceive the first antigen perceived by Ab1. Some Ab2 antibodies of this sort invigorate the safe framework to actuate defensive resistance against tumarara maantigen.
Izvo zvakaratidzirwa kuchipatara kuti chirwere chemapapu kuchengetedza inotsungirira kwazvo uye iri nani kuitiswa. Zviratidzo zvakawanda zvakakosha zvinoitika munharaunda (infusion saiti) uye zvinowanzo nyoro uye zvakapfupika. Zvisinei kuti antibody yakapihwa kuvarwere mushure mekunge mamiriro avo aparara, kutsungirira kwavo kwazara kwave nani.
Parizvino, mhando iyi yemapapu yakaipa kukura kwekudzivirira haina kusimudzirwa muIndia.
